Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 2,819 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: matched control group Clear all

Conditions: Concussion, Eye
Interventions: Not listed
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: New Haven, Connecticut • Wallingford, Connecticut

Conditions: Low Back Pain
Interventions: Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 149
States / cities: Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more

Conditions: Postpartum Depression, Postpartum Anxiety, Stress
Interventions: M.Bapp, App-based parenting education; Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Endometrial Neoplasms
Interventions: olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Female only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Concord, California • La Jolla, California + 45 more

Conditions: Depressive Disorder, Major, Anhedonia
Interventions: Aticaprant, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 46
States / cities: Tucson, Arizona • Anaheim, California • Culver City, California + 37 more

Conditions: T1DM, Brain Development
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 4 Years to 16 Years
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CK-2017357, Placebo, Riluzole 50 MG; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Fresno, California • La Jolla, California • Orange, California + 8 more

Conditions: Thrombosis
Interventions: BMS-986141, Placebo, Aspirin, Itraconazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Cypress, California • Austin, Texas

Conditions: Electronic Cigarette Use
Interventions: Health Assessments; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Spinal Cord Injury
Interventions: Heat Exposure; Other
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Central Auditory Processing Disorder, Traumatic Brain Injury, Hearing Loss
Interventions: Audiological testing; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Pain, Depression
Interventions: Quiet Focus, Health Enhancement Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor
Interventions: Sirolimus, Cyclophosphamide, Etoposide, Celecoxib; Drug
Lead sponsor: Emory University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: End Stage Renal Disease, Transplantation
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 7,029 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Dermatitis Atopic
Interventions: Dupilumab (SAR231893); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • East Windsor, New Jersey

Conditions: Clostridium Difficile Infection
Interventions: SER-109, Placebo; Biological · Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 51
States / cities: North Little Rock, Arkansas • Mather, California • Mountain View, California + 46 more

Conditions: Immune Thrombocytopenia
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 13 more

Conditions: Depression, Anxiety, Palliative Care, Caregivers, Cancer
Interventions: Problem-Solving Therapy, Attention-matched Control, In-depth interviews; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Columbia, Missouri • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Gedeon Richter Plc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Culver City, California • Atlanta, Georgia • Bloomfield Hills, Michigan + 5 more

Conditions: Anaemia
Interventions: Daprodustat (GSK1278863), Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 49
States / cities: Homewood, Alabama • Little Rock, Arkansas • Downey, California + 44 more

Conditions: Older Adults
Interventions: Slip-only training, Trip-only training, Combined slip+trip training; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 60 Years to 90 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Fesoterodine, Matching Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 645 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 13
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more

Conditions: Epilepsy
Interventions: Placebo, EQU-001; Drug
Lead sponsor: Equilibre Biopharmaceuticals B.V.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Boise, Idaho • Bethesda, Maryland • Hackensack, New Jersey + 3 more

Conditions: Healthy
Interventions: PF-06260414, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

The Effects of Concussion on Gait and Posture in Individuals With Peripheral Vision Loss

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Feasibility & Acceptability of App-based Cognitive Behavioral Therapy for Postpartum Depression Prevention

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

Brain Health and Development With T1DM

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Effects of E-cigarette Use on Health

Body Temperature in Persons With Tetraplegia When Exposed to Heat

Central Auditory Processing Disorders Associated With Blast Exposure

Mindfulness-based Cognitive Therapy vs the Health Enhancement Program for Chronic Pain and Depression; The Quiet Focus Study

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Problem-Solving Therapy for Cancer Caregivers in Outpatient Palliative Care

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Aging and Mixed Perturbation Training to Reduce Falls in Locomotion

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects